NASDAQ:PTCT PTC Therapeutics Q2 2026 Earnings Report $78.59 +0.07 (+0.09%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$78.56 -0.03 (-0.04%) As of 07/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast PTC Therapeutics EPS ResultsActual EPSN/AConsensus EPS $0.28Beat/MissN/AOne Year Ago EPSN/APTC Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$295.38 millionBeat/MissN/AYoY Revenue GrowthN/APTC Therapeutics Announcement DetailsQuarterQ2 2026Date7/30/2026TimeAfter Market ClosesConference Call DateThursday, July 30, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile PTC Therapeutics Earnings HeadlinesPTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026July 16 at 8:00 AM | prnewswire.comPTC Therapeutics (NASDAQ:PTCT) Director Mary Smith Sells 15,834 SharesJuly 14, 2026 | americanbankingnews.comForget SpaceX. THIS is Elon’s next BIG betElon Musk's next major play may not be SpaceX. A radical 'light-speed' device is transforming standard AI into what insiders are calling 'Accelerated AI' - reportedly 100 times faster and 100 times more energy efficient. The mainstream hasn't caught on yet, but related stocks have already posted gains of 133%, 217%, and as much as 320%. Early movers say this trend is just getting started.July 18 at 1:00 AM | Brownstone Research (Ad)What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 MillionJuly 13, 2026 | fool.comNeil Gregory Almstead Sells 22,161 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJuly 10, 2026 | americanbankingnews.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 17, 2026 | prnewswire.comSee More PTC Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PTC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PTC Therapeutics and other key companies, straight to your email. Email Address About PTC TherapeuticsPTC Therapeutics (NASDAQ:PTCT) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options. Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets. The company also commercializes Emflaza (deflazacort) for patients with Duchenne muscular dystrophy, expanding its portfolio in neuromuscular disease. PTC’s pipeline extends into areas such as central nervous system disorders and metabolic diseases, with programs advancing through clinical and preclinical stages to address rare forms of Rett syndrome, tyrosinemia and other genetic conditions. Headquartered in South Plainfield, New Jersey, PTC operates a global network encompassing commercial, research and manufacturing facilities across North America, Europe and Asia. The company’s leadership team is led by Stuart W. Peltz, Ph.D., who has served as Chief Executive Officer since co-founding the business. Under his guidance, PTC has established strategic collaborations and regulatory approvals that bolster its presence in key international markets, reflecting a commitment to bringing innovative therapies to patients around the world.View PTC Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/13- 07/17The Market Sold Alcoa After Earnings—But It May Be Missing the Real StoryTSMC Just Gave AI Chip Bulls Another Reason to Stay ConfidentAehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue GrowthWhy Intuitive Surgical’s Strong Quarter Still Spooked InvestorsGE Aerospace Faces a Prove-It Moment in Q2 EarningsWhy Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
